drugset / Trial / NCT00552565
Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the study is to determine the efficacy and safety of Rezular (arverapamil) in the treatment of IBS-D.
Timeline
- Start
- 2007-09
- Primary completion
- 2009-06
- Completion
- 2009-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Arverapamil | Unknown | 15 mg | Oral |
| Subject | Arverapamil | Unknown | 37.5 mg | Oral |
| Subject | Arverapamil | Unknown | 75 mg | Oral |